Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite
Not a traditional drug phase: E-consult for HIV
People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality.
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are E-consult. The registry lists allocation as randomized. People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy.
They plan to enroll about 480 people at 3 sites. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults (OPTIMIZE Lung-HIV)
Interventions: E-consult
Primary outcome (registry wording): Proportion of recommended medication changes enacted within 3 months
Who it is for (from inclusion criteria)
Ages 18 Years to any
PWH with an active prescription of ART any time in past 6 months and \<200 copies/mL within past 12 months, actively receiving care at the VA, and one of the following:
Prescribed ICS for \>90 days
Prescribed a PPI for \>90 days
Who the registry excludes
Enrolled in palliative care or hospice
If a non-VA provider is the main primary care or HIV provider
Are currently participating in a separate ongoing treatment clinical trial
There is evidence that early and aggressive treatment with antiretroviral drugs can prevent the loss of immune cell function that accompanies HIV infection. This study will use leukapheresis (drawing blood, separating out the white cells and returning the blood to the patient) to obtain blood cells from HIV-infected patients in either the acute or chronic stage of infection who are being treated with early highly active antiretroviral therapy (HAART).
This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup.
This study will investigate HIV infection and associated conditions by monitoring infected patients. The study will also serve as a means for recruiting HIV-infected individuals to NIAIDs ongoing clinical and laboratory studies and supporting the institute s infectious disease training program by providing Infectious Disease fellows with ongoing training in the management of HIV infection.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07507435?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07507435?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.